Europe Induced Pluripotent Stem Cell (iPSC) Market is projected to reach US$ 1,111.97 Million at a significant CAGR of 9.3% by 2032

𝐄𝐮𝐫𝐨𝐩𝐞 𝐈𝐧𝐝𝐮𝐜𝐞𝐝 𝐏𝐥𝐮𝐫𝐢𝐩𝐨𝐭𝐞𝐧𝐭 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 (𝐢𝐏𝐒𝐂) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐚𝐧𝐝 𝐬𝐡𝐚𝐫𝐞 𝐢𝐬 𝐜𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟓𝟎𝟎.𝟔𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 𝐚𝐧𝐝 𝐢𝐬 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐭𝐨 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐚𝐧 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐨𝐟 𝐔𝐒𝐃 𝟏,𝟏𝟏𝟏.𝟗𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐚𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐬𝐭𝐮𝐝𝐲 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. 𝐁𝐞𝐬𝐢𝐝𝐞𝐬, 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐧𝐨𝐭𝐞𝐬 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐬 𝐚 𝐫𝐨𝐛𝐮𝐬𝐭 𝟗.𝟑% 𝐂𝐨𝐦𝐩𝐨𝐮𝐧𝐝 𝐀𝐧𝐧𝐮𝐚𝐥 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐚𝐭𝐞 (𝐂𝐀𝐆𝐑) 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭𝐞𝐝 𝐭𝐢𝐦𝐞𝐟𝐫𝐚𝐦𝐞, 𝟐𝟎𝟐𝟒 - 𝟐𝟎𝟑𝟐

The increased adoption of stem cell therapy, which is fueled by the surging biotechnology industry, is the primary factor supporting the market expansion. By segmental analysis, the cardiomyocyte segment dominated the market. By country-wise insights, Germany leads the market for the Induced Pluripotent Stem Cell (iPSC) market in Europe.
The Europe iPSC market is a vital segment within the field of regenerative medicine, focusing on the utilization of iPSCs for disease modeling, drug discovery, and therapeutic development across European nations. iPSCs, reprogrammed adult cells with pluripotent properties, offer immense potential for research and clinical applications.

𝐂𝐥𝐢𝐜𝐤 𝐭𝐨 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐧𝐝 𝐃𝐫𝐢𝐯𝐞 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬:
https://www.polarismarketresearch.com/industry-analysis/europe-induced-pluripotent-stem-cell-ipsc-market/request-for-sample

𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :

The top industry players in the Europe induced pluripotent stem cell (iPSC) market are striving to gain industry share and differentiate themselves from the competition through innovation and strategic partnerships. Some of the major industry participants offering their products/services in the market include:

• Axol Bioscience Ltd.
• Charles River Laboratories International, Inc.
• Corning Incorporated
• FUJIFILM Corporation
• Horizon Discovery Ltd.
• LumaCyte
• R & D Systems, Inc.
• REPROCELL Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐬:

• The global Europe induced pluripotent stem cell (iPSC) market size was valued at USD 500.62 million in 2023 and is projected to grow to USD 1,111.97 million by 2032.
• The market is projected to expand at a compound annual growth rate (CAGR) of 9.3% during the forecast period from 2024 to 2032.
• The industry is primarily segmented based on derived cell, workflow, application, and country.
• The countries covered in the report include the UK, France, Germany, Italy, Spain, Netherlands, Russia and the rest of Europe.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
https://www.polarismarketresearch.com/buy/3874/2

𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

Induced pluripotent stem cells, also referred to as iPS or iPSCs, are a type of pluripotent stem cell derived from skin or blood cells. These cells can be procured by reprogramming human and animal differentiated cells. Induced pluripotent stem cells have the same characteristics as embryonic stem cells. As such, they can self-renew and differentiate into various cell types within the body.

Also, these cells play a vital role in disease modeling, owing to their close resemblance to the cell donor. Along with disease modeling, iPSCs are used for gene therapy, toxicity testing, and drug discovery. Furthermore, they find extensive use in the treatment of cardiovascular diseases and different cancer types.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬

The continuous integration of novel technologies with existing knowledge has led to the development of more realistic systems. These advancements, which include the use of iPSCs in regenerative medicine applications, disease modeling using iPSCs, organic models derived from iPSCs, and iPSCs for drug discovery applications, are greatly enhancing our understanding of these sophisticated processes. The rising advances in technology boost the European induced pluripotent stem cell (iPSC) market growth.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:
https://www.polarismarketresearch.com/industry-analysis/europe-induced-pluripotent-stem-cell-ipsc-market

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

𝐁𝐲 𝐃𝐞𝐫𝐢𝐯𝐞𝐝 𝐂𝐞𝐥𝐥
• Hepatocytes
• Fibroblasts
• Neural Cells
Excitatory Neurons
Inhibitory Neurons
• Amniotic Cells
• Cardiomyocytes
• Others

𝐁𝐲 𝐖𝐨𝐫𝐤𝐟𝐥𝐨𝐰

• Reprogramming
• Cell Culture
• Cell Characterization / Analysis
• Engineering
• Others

𝐁𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧

• Manufacturing
• Academic Research
• Drug Development & Discovery
• Toxicity Screening
• Regenerative Medicine

𝐄𝐮𝐫𝐨𝐩𝐞 𝐈𝐧𝐝𝐮𝐜𝐞𝐝 𝐏𝐥𝐮𝐫𝐢𝐩𝐨𝐭𝐞𝐧𝐭 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 (𝐢𝐏𝐒𝐂) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• ·The Cardiomycocytes segment has dominated market is experiencing fastest growth due to its capacity to generate cardiomyocyte tissue, capable of stimulating heart contractions, presents opportunities for advancements in regenerative research.

• The cell culture segment has dominated and is poised for substantial expansion with a significant CAGR over the projected period owing to its wide applications and progress in stem cell research such as regenerative medicine, drug discovery, and toxicity testing

• Germany is currently at the forefront of the Induced Pluripotent Stem Cell (iPSC) market in Europe, owing to its global technology hub and strong emphasis on innovation and research and development.

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

𝐓𝐞𝐥𝐞𝐡𝐞𝐚𝐥𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/telehealth-market

𝐁𝐫𝐞𝐚𝐬𝐭 𝐈𝐦𝐩𝐥𝐚𝐧𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-breast-implants-market

𝐁𝐥𝐨𝐜𝐤𝐜𝐡𝐚𝐢𝐧 𝐈𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/blockchain-in-healthcare

𝐂𝐚𝐫 𝐓 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

Polaris Market Research
Phone: +1-929-297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.